戴海萍  

个人简介：戴海萍，主任医师，副教授，硕士研究生导师。2008年毕业于苏州大学，医学博士，2013年获得“江苏省卫生国际(地区)交流支撑计划”资助，赴德国微生物和细胞培养研究所（Leibniz Institute DSMZ- German Collection of Microorganisms and Cell Cultures）访学一年。

擅长疾病：白血病靶向和免疫治疗

科研情况：先后主持2项国家自然科学基金，1项江苏省自然科学基金。参与5项国家自然科学基金。获江苏省省科技进步奖一等奖1项，市级科技成果奖2项。在国内外学术期刊发表以第一/通讯（含共同）发表SCI论文30余篇。在转化研究领域，授权国家发明专利1项。

教育背景（从大学本科开始，按时间倒序排序）：

1. 2005/09—2008/06 苏州大学，内科学（血液病学）专业，获医学博士学位
2. 1998/09—2005/06 南京中医药大学，中医七年制专业（本硕连读），获临床医学硕士学位

科研与学术工作经历：

1. 2021/1-迄今 苏州大学附属第一医院血液科 主任医师
2. 2013/12-2020/12 苏州大学附属第一医院血液科 副主任医师
3. 2009/8-2013/11 苏州大学附属第一医院血液科 主治医师
4. 2008/8-2009/07 苏州大学附属第一医院血液科 住院医师

研究领域：白血病靶向和免疫治疗

取得研究成果和获得学术奖励情况：

近5年发表的5篇代表性论著

1.Wan CL#, Liu YQ#, Liu FT#, Huang YH, Cao HY, Huang SM, Tan KW, Ge SS, Wang M, Liu MJ, Wang ZH, Li Z, Xue SL*, Dai HP*. Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification. Blood Cancer J. 2024 Aug 23;14(1):144.
2.Li YY#, Ge SS#, Huang YH#, Xu MZ, Wan CL, Tan KW, Tao T, Zhou HX, Xue SL*, Dai HP*. Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study. Blood Cancer J. 2024 Jan 18;14(1):12.
3.Wang M#, Cao HY#, Tan KW#, Qiu QC, Huang YH, Ge SS, Wang ZH, Chen J, Tang XW, Wu DP, Xue SL*, Li Z*, Dai HP*. Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study. Blood Cancer J. 2023 Nov 27;13(1):173.
4.Wang Q#, Cai WZ#, Wang QR#, Zhu MQ, Yan LZ, Yu Y, Bao XB, Shen HJ, Yao H, Xie JD, Zhang TT, Zhang L, Xu XY, Shan Z, Liu H, Cen JN, Liu DD, Pan JL, Lu DR, Chen J, Xu Y, Zhang R, Wang Y, Xue SL, Miao M, Han Y, Tang XW, Qiu HY, Sun AN, Huang JY, Dai HP*, Wu DP*, Chen SN*. Integrative genomic and transcriptomic profiling reveals distinct molecular subsets in adult mixed phenotype acute leukemia. Am J Hematol. 2023;98(1):66-78.
5.Dai HP, Kong DQ, Shen HJ, Cui W, Wang Q, Li Z, Yin J, Kang LQ, Yu L, Wu DP, Tang XW. CAR-T cell therapy followed by allogenic hematopoietic stem cell transplantation yielded comparable outcome between Ph like ALL and other high-risk ALL. Biomark Res. 2023;11(1):19.

近5年发表的其余论著
1.Liu MJ#, Tan KW#, Cao HY#, Huang SM, Qian CS, Xue SL*, Dai HP*, Gong WJ*. Patients with CML in the lymphoid blastic phase have inferior response to anti-CD19 CAR T-cell therapy compared to de novo Ph-positive B cell acute lymphoblastic leukemia. Hemasphere. 2024 Feb 27;8(2):e49.
2.Wan CL#, Huang YH#, Huang SM#, Xu YL, Tan KW, Yan-Qiu, Shen XD, Ge SS, Cao HY, Li YY, Liu SB, Qi JJ, Dai HP*, Xue SL*. Investigations of the prognostic value of RUNX1 mutation in acute myeloid leukemia patients: Data from a real-world study. Leuk Res. 2024 ;139:107483.
3.Lu J#, Qiu H#, Wang Y#, Zhou X#, Dai H#, Lu X, Yang X, Gu B, Hong M, Miao M, Lu R, Wang J, Wu Q, Xue M, Wang Y, Deng A, Shen Y, Liu Y, Dou X, Lei Y, Wu D*, Zhu Y*, Chen S*. Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial. J Hematol Oncol. 2024, (2024) 17:79

4.Han LL, Yang X, Dai H*, Zhu J*. A Case of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Coexistence of the JAK2V617F Clone. Turk J Haematol. 2024 May 30;41(2):123-125.
5.Ma Y#, Dai H#, Cui Q#, Liu S, Kang L, Lian X, Cui W, Yin J, Liu L, Cai M, Yu L*, Wu D*, Tang X*. Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients. Exp Hematol Oncol. 2023;12(1):36.
6.Huang YH, Wan CL, Dai HP#, Xue SL#. Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma. Ann Hematol. 2023;102(8):2001-2013.
7.Cao HY*, Chen H*, Liu SB*, Gong WJ, Qian CS, Zhang TT, Wan CL, Huang SM, Xu N, Dai HP#, Xue SL#. Blinatumomab therapy for the treatment of B-cell acute lymphoblastic leukemia patients with central nervous system infiltration. Front Immunol. 2023;14:1181620.
8.Tan KW*, Zhu YY*, Qiu QC, Wang M, Shen HJ, Huang SM, Cao HY, Wan CL, Li YY, Dai HP#, Xue SL#. Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review. Ann Hematol. 2023 Sep;102(9):2397-2402.
9.Ge SS*, Qiu QC*, Dai HP*, Shen XD, Wu TM, Du JH, Wan CL, Shen HJ, Wu DP#, Xue SL#, Liu SB#. Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy. Br J Haematol. 2023 Aug;202(3):539-549.
10.Zhu JF*, Dai HP*, Zhang QQ, Yin J, Li Z, Cui QY, Tian XP, Liu SN, Jin ZM, Zhu XM, Wu DP#, Tang XW#. Efficacy and safety of decitabine combined with HAAG (homoharringtonine, aclarubicin, low-dose cytarabine and G-CSF) for newly diagnosed acute myeloid leukemia. Front Oncol. 2022 Oct 12;12:998884.
11.Cao HY, Li L, Xue SL#, Dai HP#. Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy. Hematol Oncol. 2023 Aug;41(3):301-309.
12.Ma YJ*, Dai HP*, Cui QY, Cui W, Zhu WJ, Qu CJ, Kang LQ, Zhu MQ, Zhu XM, Liu DD, Feng YF, Shen HJ, Liu TH, Qiu HY, Yu L, Wu DP#, Tang XW#. Successful application of PD-1 knockdown CLL-1 CAR-T therapy in two AML patients with post-transplant relapse and failure of anti-CD38 CAR-T cell treatment. Am J Cancer Res. 2022 Feb 15;12(2):615-621. eCollection 2022.
13.Cui Q*, Liang P*, Dai H*, Cui W, Cai M, Ding Z, Ma Q, Yin J, Li Z, Liu S, Kang L, Yao L, Cen J, Shen H, Zhu M, Yu L, Wu D#, Tang X#. CD38-directed CAR-T cell therapy: A novel immunotherapy targeting CD38- positive blasts overcomes TKI and chemotherapy resistance of myeloid chronic myeloid leukemia in blastic phase. Front Immunol. 2022 Nov 29;13:1012981.
14.Cao X*, Dai H*, Cui Q, Li Z, Shen W, Pan J, Shen H, Ma Q, Li M, Chen S, Chen J, Zhu X, Meng H, Yang L, Wu D#, Tang X#. CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia Exp Hematol Oncol. 2022 Sep 29;11(1):67.
15.Dai HP*, Cui W*, Cui QY, Zhu WJ, Meng HM, Zhu MQ, Zhu XM, Yang L, Wu DP#, Tang XW#. Haploidentical?CD7?CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma. Biomark Res. 2022 Feb 7;10(1):6.
16.Wang Q*, Zhang L*, Zhu MQ*, Zeng Z, Fang BZ, Xie JD, Pan JL, Wu CX, Wu N, Zhang R, Chen SN#, Dai HP#. A Recurrent Cryptic MED14-HOXA9 Rearrangement in an Adult Patient With Mixed-Phenotype Acute Leukemia, T/myeloid, NOS. Front Oncol. 2021 Jul 22;11:690218.
17.Zhang XY*, Dai HP*, Zhang L, Liu SN, Dai Y, Wu DP#, Tang XW#. MRD-Negative Remission Induced in EP300-ZNF384 Positive B-ALL Patients by Tandem CD19/CD22 CAR T-Cell Therapy Bridging to Allogeneic Stem Cell Transplantation. Onco Targets Ther. 2021 Oct 29;14:5197-5204.
18.Zhang XY*, Dai HP*, Li Z, Yin J, Lang XP, Yang CX, Xiao S, Zhu MQ, Liu DD, Liu H, Shen HJ#, Wu DP#, Tang XW#. Identification of STRBP as a Novel JAK2 Fusion Partner Gene in a Young Adult With Philadelphia Chromosome-Like B-Lymphoblastic Leukemia. Front Oncol, 2021 Jan 11;10:611467.
19.Wang Q*, Dai HP*, Liu DD, Xie JD, Yao H, Ding ZX, Tao TT, Chen SN,# Zhang R#. Efficacy of Ruxolitinib in a patient with Myelodysplastic/myeloproliferative Neoplasm Unclassifiable and Co-mutated JAK2, SF3B1 and TP53. Leuk Res Rep. 2020 Oct 30;14:100229.
20.Dai HP, Yin J, Li Z, Yang CX, Cao T, Chen P, Zong YH, Zhu MQ, Zhu XM, Xiao S, Wu DP#, Tang XW#. Rapid Molecular Response to Dasatinib in a Pediatric Relapsed Acute Lymphoblastic Leukemia with NCOR1-LYN Fusion. Front Oncol, 2020 Mar 20;10:359.
21.Yang X*, Dai H*, Kang L, Qu C , Li Z, Yin J, Qiu H, Fu C, Han Y, Jin Z, Ma X, Zhu X, Yu L, Wu D#, Tang X#. Donor origin CAR19 T cell infusion for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation. Hematol Oncol. 2019 Dec, 37(5):655-658.
22.戴海萍，沈宏杰, 李正, 崔巍, 崔庆亚, 郦梦云, 陈思帆, 朱明清, 吴德沛, 唐晓文。嵌合抗原受体T细胞序贯异基因造血干细胞移植治疗Ph样急性淋巴细胞白血病21例的疗效及安全性。中华血液学杂志，2024，45(1):35-40.
23.戴海萍，李正，尹佳，刘明红，朱霞明，吴德沛，唐晓文。造血干细胞移植治疗Ph样急性淋巴细胞白血病五例并文献复习。中华器官移植, 2019, 40(3): 144-147.

主持或参加科研项目（课题）及人才计划项目情况：

1.国家自然科学基金委员会, 面上项目, 81873443, 抗急性T淋巴细胞白血病的CXCR4赋能的CCR9嵌合抗原受体T（CXCR4 αCCR9-CART）细胞疗法研发, 2025-01-01 至 2028-12-31, 60万元, 在研, 主持。
2.白求恩公益基金会, 白求恩 血液科研能力建设项目, BCF-IBW-XY-20220930-08。T-ALL中BCL-2抑制剂耐药模型的构建及耐药机制研究, 2022-09至2023-12, 10万元, 结题, 主持。
3.江苏省自然科学基金，面上项目，BK20141202，miR-130a参与核心结合因子急性髓系白血病致病的机制研究，2014.7-2017.6，10万元，已结题，主持。
4.国家自然科学基金委员会, 青年基金，81000222，桩蛋白leupaxin在白血病发病中的作用及其机制研究，2011.1-2013.12，19万元，已结题，主持。
5.国家自然科学基金委员会, 面上项目, 82070162, 干扰素-α调控CAR-T细胞和内源性T细胞协同抗难治复发B-ALL的免疫效应及机制研究, 2021-01-01 至 2024-12-31, 54万元, 在研，参与。
6.国家自然科学基金委员会, 面上项目，81873443，低剂量地西他滨上调白血病细胞表达GADD45A介导预处理增敏对难治复发AML抑制后生存改善的作用机制研究，2019.1-2022.12，60万元，在研，参与。
7.国家自然科学基金委员会, 青年基金，81600114，EP300/ZNF384融合基因在急性白血病中发病机制的研究，2017.1-2020.12，18万元，已结题，参加。
8.国家自然科学基金委员会, 面上项目，81470296，DNA解旋酶 BRIP1在慢性粒单核细胞白血病及急性髓系白血病发生发展和预后中的作用研究，2015.1-2018.12，75万元，已结题，参与。
9.国家自然科学基金委员会, 青年基金，81100332，恶性血液病中20q-的共同缺失区域、该区域内相关基因、基因表达谱及其临床意义研究，2012.1-2014.12，23万元，已结题，参与。

论著之外的代表性研究成果和学术奖励：

1.薛胜利; 刘松柏; 邱桥成; 葛帅帅; 王隽; 杜佳慧; 戴海萍 ; 一种小分子化合物及其在制备治疗FLT3突变型白血病药物中的应用, 2023-12-8, 中国, 一种小分子化合物及其在制备治疗FLT3突变型白血病药物中的应用 (专利)
2.戴海萍 (5/9); CART细胞免疫疗法治疗恶性血液病关键技术的优化和推广, 苏州市医学会, 科技进步, 2023 (科研奖励)
3.戴海萍(7/9); 白血病中新的染色体异常、融合基因和白血病细胞系的研究, 江苏省人民政府, 科技进步, 省部一等奖, 2009 (科研奖励)
4.戴海萍 (6/9); 白血病中新的染色体异常、融合基因和白血病细胞系的研究和应用, 苏州市人民政府,科技进步, 其他, 2010 (科研奖励)